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There is evidence that the a-synucleinopathies Parkinson's disease (PD) and the Parkinson variant of
multiple system atrophy (MSA-P) overlap at multiple levels. Both disorders are characterized by depo-
sition of abnormally phosphorylated ﬁbrillar a-synuclein within the central nervous system suggesting
shared pathophysiological mechanisms. Despite the considerable clinical overlap in the early disease
stages, MSA-P, in contrast to PD, is fatal and rapidly progressive. Moreover recent clinical studies have
shown that surrogate markers of disease progression can be quantiﬁed easily and may reliably depict the
rapid course of MSA. We therefore posit that, MSA-P may be exploited as a ﬁlter barrier in the devel-
opment of disease-modifying therapeutic strategies targeting common pathophysiological mechanisms
of a-synucleinopathies. This approach might reduce the number of negative phase III clinical trials, and,
in turn, shift the available resources to earlier development stages, thereby increasing the number of
candidate compounds validated.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Parkinson's disease (PD) and multiple system atrophy (MSA) are
two distinctive neurodegenerative disorders characterized by a-
synuclein (aSYN) inclusion pathology, although some genetic PD
variants show only little or no aSYN inclusion pathology, particu-
larly PARK2 and LRRK2 mutation carriers [1]. During the last two
decades numerous candidate neuroprotective agents have been
evaluated in large randomized controlled PD trials. Unfortunately,
none of them proved effective either reﬂecting a lack of neuro-
protective efﬁcacy or shortcomings of preclinical models, outcome
measures including surrogate markers and trial design issues [2].
Novel strategies to overcome the deadlock in PD interventional
trials are therefore needed. We here posit, based on overlappingnnsbruck Medical University,
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Ltd. This is an open access article ufeatures [3], that drug discovery in PD can be accelerated by
conceptualizing the parkinsonian variant of MSA (MSA-P) as a
template for the validation of joint therapeutic strategies targeting
aSYN aggregation. Hereinafter, we will review overlaps in genetics,
pathology, etiopathogenesis, and clinical presentation, discuss trial
considerations and ﬁnally suggest a modiﬁed drug development
approach based on the quick win, fast fail paradigm [4].2. Genetic overlap
Rare familial forms of PD generated important insights into the
genetic underpinnings of parkinsonism. The seminal description by
Polymeropoulos et al. demonstrating that mutations in SNCA,
coding for aSYN, are a cause of PD has revolutionized the ﬁeld for
three reasons [5]. First, it clearly disproved the long held hypothesis
that PD pathogenesis is not genetic in nature; second, it provided a
robust target to generate experimental cell and animal models and
third, it offered the ﬁrst clue that aSYN plays a pivotal role in
neurodegeneration.
Systematic evaluations of the SNCA locus in PD and MSA have
further advanced our understanding of a-synucleinopathies sub-
stantially. In addition to missense mutations, multiplicationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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demonstrated to cause familial PD [6e8]. Although thesemutations
have not been detected in MSA, the presence of GCI-like inclusions
as well as clinical phenotypes reminiscent of MSA have been noted
in some SNCA multiplication family members suggesting that an
increase in aSYN expression level could be involved in MSA path-
ogenesis [8,9]. This notion is supported by observations in trans-
genic mouse models overexpressing aSYN under oligodendroglial
promoters, where GCIs as well as neurodegeneration and clinical
features of MSA are observed [10]. However, to date gene expres-
sion studies of small size did not reveal SNCA expression changes in
pathology-proven MSA cases [11], and the role of changes in aSYN
expression or degradation in MSA pathogenesis remains elusive.
A genome-wide association study (GWAS) has linked single
nucleotide polymorphisms at the SNCA locus to an increased risk
for PD [12]. Subsequently, the top risk variants from this study were
tested in about 500 MSA cases and 4000 controls and signiﬁcant
association for two variants in SNCA were detected [13]. However,
preliminary results of the ﬁrst MSA GWAS suggest that the SNCA
risk loci will not reach genome-wide signiﬁcance reﬂecting either
insufﬁcient power of the MSA GWAS or ethnic confounders in
previous studies [14]. More recently, Kiely et al. [15] reported a
SNCA p.G51D mutation in a British family with autosomal-
dominant inheritance sharing neuropathological features charac-
teristic of both PD and MSA and thereby providing a possible link
between MSA and PD.
These ﬁndings indicate that aSYN is presumably a key player in
neurodegenerative processes in PD and MSA. Furthermore, the
intriguing observation of SNCA multiplications causing MSA-like
glial pathology point towards common aSYN-related pathophysi-
ological mechanism that we will discuss below.
3. Pathologic overlap
Immunohistochemical studies revealed that abnormal aSYN
aggregates are found in neurons and axons in PD brains [8],
whereas, aSYN aggregates in MSA are predominantly seen in the
cytoplasm of oligodendrocytes. The term a-synucleinopathies
was coined to embrace these clinicopathological entities [16].
While the cellular distribution of the aggregates is clearly
different, there is still important pathological overlap. In both, PD
and MSA-P, neurodegeneration is associated with the Lewy body
and GCI burden as well as the increase of soluble aSYN in sub-
stantia nigra and striatum [17]. In addition, apart from the
apparent overlap in degeneration of the dopaminergic nigros-
triatal system, involvement of the central and peripheral auto-
nomic nervous system including the dorsal motor vagal nucleus,
autonomic parts of the spinal cord, as well as the peripheral
autonomic nervous system (e.g. the cardiac and enteric systems),
is common to both PD and MSA-P [17e20].
Intriguingly, brainstem LBse a classical pathological hallmark of
PD e were also reported in MSA and, vice versa, GCI pathology
occurred in familial PD cases with rapid disease progression
[8,9,21]. The molecular basis of these co-existing pathologies re-
mains to be elucidated.
Overall, these neuropathological similarities provide further
evidence that aSYN fragments are able to interfere with physio-
logical processes thereby triggering neurodegenerative processes
irrespective of the underlying inclusion pathology.
4. Common pathogenic pathways
The exact mechanisms of aSYN-triggered neurodegeneration
are not completely understood, but studies point to common
principles that may underlie disease development and progression.At the molecular level aSYN is a natively unfolded, soluble cytosolic
protein. Biochemical analyses of aSYN deposits in MSA and PD
revealed abnormal phosphorylation at the serine-129 residue, a
mechanism that is known to increase aSYN aggregation propensity,
as well as the precipitation of ubiquitinated ﬁbrils made up of
proteinase K resistant, b-sheeted aSYN [22,23]. Experimental evi-
dence suggests that misfolded aSYN can inﬂuence the viability of
cells affected by aggregation pathology in numerous fashions
including the disruption of cytoskeleton integrity, dysfunction of
the ubiquitin-proteasome system and autophagy pathways, by
causing mitochondrial dysfunction, or by disruption of the endo-
plasmic reticulum-Golgi vesicular trafﬁcking and membrane
integrity [24,25]. In addition, it was recently proposed that pre-
synaptic aSYN deposits generate a dying back type of neuronal loss
[26e28]. In parallel, loss of dendritic spines appears to accompany
the presynaptic aSYN pathology in Dementiawith Lewy Bodies [29]
and loss of dendritic spines was also reported for striatal neurons in
post-mortem PD brains [30]. These ﬁndings are consistent with a
notion that aSYN aggregate-related synaptic dysfunction may
constitute the starting point of neurodegeneration in LB disorders
[29]. In contrast, MSA-associated neuronal cell death appears sec-
ondary to the aSYN-related oligodendroglial dysfunction [31].
Remarkably, glial ﬁlamentous inclusions in PD brains affecting
oligodendroglial as well as astroglial cell populations were immu-
noreactive for aSYN and correlated with the severity of nigral cell
loss [32].
The temporal evolution of neuropathology in PD [33], combined
with the post-mortem observation of aSYN pathology within fetal
grafts of transplanted PD patients [34,35] implicate that a trans-
mission of aSYN (or its toxic truncated forms) from cell to cell may
be a critical mechanism underlying disease spread in a-synuclei-
nopathies. Interestingly, converging preclinical evidence indicates
the ability of aSYN to spread throughout the PD brain in a prion-like
fashion [36,37]. In MSA, the origin of oligodendroglial aSYN re-
mains elusive as illustrated by lack of evidence of aSYN expression
in oligodendrocytes of healthy and MSA brains [38]. This gives rise
to the notion that aSYN is taken up into oligodendrocytes from
extracellular space with aSYN most likely being secreted by
neurons.
In addition to direct neurotoxic effects of intra- and extracel-
lular aSYN accumulation, it is proposed that aSYN may trigger
gliosis which is associated with enhanced oxidative stress.
Oxidative and nitrative stress seem to play a pivotal role in both
PD and MSA pathogenesis either directly affecting neuronal sur-
vival or resulting in posttranslational modiﬁcations of aSYN which
consequently leads to accelerated protein aggregation and
enhanced toxicity [39e41]. In PD an increasing body of evidence
delineates the role of microglial and astroglial responses [41].
Similarly, MSA in vivo and post-mortem data also support the
involvement of glial mechanisms and transgenic models conﬁrm
the role of inﬂammatory signaling in the pathogenesis of GCI-
related neurodegeneration [42]. However, further aspects of pro-
inﬂammatory mechanisms in the pathogenesis of PD and MSA
need to be addressed to deﬁne potent candidate targets for neu-
roprotection [39,41].
In summary, despite the obvious notion of aSYN being involved
in neurodegeneration in PD and MSA, several molecular mecha-
nisms overlap. Both disorders are characterized by spreading of
aSYN pathology with PD showing a pattern of neuron-to-neuron
aSYN propagation. In MSA, neuronal aSYN is passed to oligoden-
drocytes as suggested by the lack of SNCA expression in glial cells
[38]. Furthermore, posttranslational modiﬁcations of aSYN and
neuroinﬂammatory processes are comparable in MSA and PD.
Major genetic, morphologic, and pathogenic overlaps between
idiopathic PD and MSA-P are also summarized in Fig. 1.
Fig. 1. Overlapping and discriminating features of MSA and idiopathic PD. The ﬁgure shows distinguishing and overlapping features of MSA-P and Parkinson's disease at the
pathogenic, pathologic and clinical level. Unique MSA-P features are emphasized by a red highlight, PD features are shaded in blue and overlapping features are presented on a
purple background.
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Alongside the apparent overlap in motor features, clinicopath-
ological and prospective clinical studies indicate thatMSA-P and PD
share non-motor symptoms as well [43]. Due to this overlap, PD
and MSA-P are frequently indistinguishable in the early disease
stages e even when formal criteria are applied [3]. Distinguishing
and overlapping clinical features are shown in Fig. 1.
5.1. Motor features
The diagnosis of PD hinges on the presence of bradykinesia
together with one out of three additional hallmark features
including rest tremor, rigidity, and postural instability [44]. In MSA-
P all of these features may occur although pill-rolling rest tremor is
uncommon [45] and, in contrast to PD, postural instability emerge
early within the ﬁrst years into the disease-course in MSA-P [46].
One of the key-characteristics of PD is the marked and persistent
levodopa response with drug-induced motor complications at later
disease stages [44]. Despite MSA-P being considered levodopa-
unresponsive, there is an increasing body of evidence suggesting
that MSA patients receiving levodopa may show a beneﬁcial (albeit
mostly self-limited) motor response and some of these patients will
experience levodopa-induced motor complications [3,45]. These
ﬁndings suggest that a subgroup of MSA-P patients may present
with a PD-like syndrome. The latter notion is further supported by a
case series of pathologically provenMSA-P patients exhibiting slow
progression and prolonged survival of more than 15 years [47].
5.2. Non-motor features
Non-motor features are common to both disorders involving
autonomic, sleep and neuropsychiatric domains. As suggested for
premotor MSA [43], orthostatic hypotension (OH) may precede the
onset of motor symptoms in some PD patients as well [48]. Urinary
problems emerge almost universally in PD and MSA. Although time
course and severity of urinary symptoms are obviously different,
both PD and MSA-P share similar urological features includingfrequency, urgency, urge incontinence and nocturia reﬂecting a
prominent sphincter-detrusor dyssynergia [49]. Erectile dysfunc-
tion in men and genital hyposensitivity in women are the earliest,
but usually not the presenting features of MSA-P [50], and sexual
dysfunction may also occur as an early symptom in PD [51].
Intriguingly, a retrospective analysis of a large cohort of men
demonstrated that erectile dysfunction is associated with an
increased risk of developing PD [52]. Also both MSA-P and PD pa-
tients suffer from reduced bowel frequency, difﬁculties in evacua-
tion and rarely fecal incontinence [53]. Nevertheless, a pattern of
widespread, severe and rapidly progressive generalized autonomic
failure with adrenergic dysfunction clearly points towards a diag-
nosis of MSA [54].
Sleep disorders including rapid eye movement sleep behavior
disorder (RBD) are common in PD andMSA-P. In fact, it appears as if
a-synucleinopathies share a common RBD phenotype often with
premotor onset [55,56].
In contrast to the long-held belief, clinicopathological evidence
proved that MSA patients may develop cognitive dysfunction and
dementia [57]. Additionally, a recently published prospective
neuropsychological study found that approximately 20% of MSA
patients score below the ﬁfth percentile on the Mattis dementia
rating scale [58]. Nevertheless, dementia is much more common in
PD compared with MSA [59], however, the proﬁle of cognitive
impairment is comparable in PD and MSA as both disorders exhibit
prominent impairment in frontal executive functions [58,59].
Another distinction between MSA and PD is the olfactory sense
with MSA patients showing intact or mildly impaired olfaction
only, whereas most PD patients are hyposmic or sometimes
anosmic with deﬁcits affecting odor detection, discrimination and
identiﬁcation. Even more interestingly, olfactory disturbances
precede the motor-onset of PD [44,60].
5.3. Disease progression
Rapid disease progression in MSA-P usually leads to loss of in-
dependent ambulation within the ﬁrst few years of disease while
PD patients usuallymaintainmobility and functional independence
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Although natural motor progression of PD is not well documented,
data on the short-term rate of progression are available due to
placebo-controlled trials suggesting accelerated progression of
motor dysfunction in the early course of the untreated disease.
These data are consistent with observations from the pre-levodopa
era reporting latencies to Hoehn and Yahr stage IV and V of 9 and 14
years, respectively. The introduction of levodopa has signiﬁcantly
delayed the disability milestones and reduced mortality in PD [61].
In contrast, MSA-P patients experience rapid motor decline
regardless of levodopa therapy [45], most likely reﬂecting the
widespread striatal involvement. Furthermore, wheelchair-
dependency was reported to occur on average after 6.7 years
from disease-onset in MSA patients. Other clinical milestones of
pre-terminal disease appeared in rapid succession at 5.3 years after
disease-onset [57]. Another characteristic feature occurring in both
disorders are falls. In contrast to MSA, PD patients usually suffer
from falls in advanced stages only, however, a retrospective clini-
copathological study demonstrated that latency to onset of recur-
rent falls but not their duration differentiated PD from MSA [46].
Finally, disease progression in PD is characterized by the increasing
prevalence of non-motor symptoms, in particular neuropsychiatric
features and autonomic failure [59]. In MSA, autonomic failure
including urogenital disturbances and OH occurs early in the course
of the disease and in a substantial proportion of cases it even pre-
cedes motor onset [43]. Furthermore autonomic failure, particu-
larly urogenital symptoms, appear to worsen over time [45,62].
Clinicopathological studies in neurodegenerative diseases are
limited by the inability to follow patients longitudinally and by the
difﬁculty of associating pre-mortem clinical symptoms to post-
mortem ﬁndings. In contrast, brain imaging has the potential to
study lesion progression in vivo. This has been repetitively per-
formed in parkinsonian disorders [63e65]. In PD, functional imag-
ing studies using bothﬂuorodopa- and b-CITsingle photon emission
computerized tomography (SPECT) estimated an annual loss of
signal in the range of 5%e10% per year [66,67] which is considerably
slower thanprogression rates determined inMSA-P [68]. Atrophy as
determined by magnetic resonance imaging (MRI) is more rapid in
MSA-P as compared with PD with regional atrophy rates ranging
from 1.0 to 2.5% decline per year in MSA and 0.3e0.8% decline per
year in PD [63]. In addition, a signiﬁcant increase in diffusivity over
time was observed in MSA patients only [69e71].
6. Trial considerations
In the absence of accurate biomarkers that are able to monitor
PD disease progression, neuroprotection and disease-modiﬁcation
trials have been restricted to clinical outcomes which have
important shortcomings including the fact that disease-speciﬁc
rating scales are nonlinear in nature and may fail to detect pro-
gression of important disease features [2]. To this end, interven-
tional trials utilizing clinical milestones as primary outcome
measures would be helpful. Obviously, latter studies are not
feasible in PD with latencies to clinical milestones exceeding a
decade. However, such trials may succeed in MSA with pre-
terminal clinical milestones being reported to appear in rapid
succession shortly after diagnosis [57]. In addition, PD progression
as measured by validated rating scales is slow [61], whereas the
motor decline in MSA as determined by the disease-speciﬁc Uniﬁed
MSA Rating Scale is much more rapid [45]. As mentioned before,
trials aiming at disease-modiﬁcation in PD require extensive study
periods of at least two years due to the slow progression. In that
regard and with excellent symptomatic treatment options at our
disposal, long-term placebo-controlled clinical trials in PD have
raised serious ethical concerns.Serial brain imaging could be instrumental in the context of
future interventional trials because monitoring progression by
imaging parameters has been shown to reduce the required sample
size. The progression of structural imaging in PD is slow hampering
its utility in PD disease-modiﬁcation trials [63], whereas the
continuous signal decline in presynaptic dopamine transporter
imaging warranted the use of dopamine transporter SPECT in PD
trials. Dopamine transporter SPECT was exploited to document
nigrostriatal degeneration in two independent clinical trials sug-
gesting disease-modifying effects in both of the two studied com-
pounds [72,73]. However, the signal alterations were subsequently
attributed to dopamine transporter expression dynamics in the
levodopa treated control group [74e76]. By contrast, functional and
morphologic imaging parameters were shown to be rapidly pro-
gressive in MSA. Thus far, three MSA trials used neuroimaging as a
secondary outcome measure. An efﬁcacy and safety study on
lithium (NCT00997672) compared micro- and macrostructural MRI
parameters before and after the treatment, including voxel-based
morphometry, resting functional MRI, diffusion tensor imaging,
and magnetic resonance spectroscopy, but was terminated pre-
maturely due to safety concerns. Another clinical trial, testing the
efﬁcacy of rasagiline in MSA-P (EudraCT 2009-014644-11),
compared rates of progression of putaminal abnormalities in an
imaging sub-study exploiting diffusion-weightedMRI. The imaging
results showed progressive increase in putaminal apparent diffu-
sion coefﬁcient values over time and supported the clinical obser-
vation of lacking treatment effect [77]. A recent study
(NCT00911365) on mesenchymal stem cells (MSC) in patients with
MSA deﬁned changes in cerebral glucose metabolism and gray
matter density as determined by ﬂuorodeoxyglucose positron
emission tomography and MRI-based morphometry, respectively,
as secondary outcome measures. The results revealed a more pro-
nounced decrease in cerebral glucose metabolism and gray matter
density at 360 days relative to baseline in the cerebellum and the
cerebral cortical areas in the placebo group compared to the MSC
group [78].
Finally, bearing recent experimental approaches counteracting
intra- and extracellular aSYN toxicity in mind, in vivo visualization
of aSYN deposition has become a recognized research target. MSA
seems to be an ideal candidate for these imaging approaches
possibly showing a better signal-to-noise ratio due to the greater
aSYN load. In fact, Kikuchi and co-workers [79] reported that GCIs
may be visualized in vivo in MSA patients using positron emission
tomography and the amyloid ligand 11C-2-[2-(2-
dimethylaminothiazol-5-yl)ethenyl]-6-[2-(ﬂuoro)ethoxy]benzox-
azole. Nevertheless, additional studies are urgently required to
establish imaging of intracellular aSYN deposits as surrogate
marker in future interventional trials.
The rapid clinical progression of MSA-P and the lack of con-
founding symptomatic therapies in MSA as well as the presence of
rapidly progressive and reliable surrogate markers are unique ad-
vantages of using MSA patients to screen for disease-modifying
agents.
7. Discussion
Clinical development (phases IeIII) account for approximately
63% of the costs for each new compound launched with 53% arising
from phase II until launch [4]. It seems natural that clarifying the
neuroprotective potential earlier in the drug development process
would increase the number of evaluated interventional treatments.
Based on the trial considerations delineated above, we suggest that
MSA-P could be employed to clinically validate compounds, which
were shown to interfere with joint pathophysiological mechanisms
in preclinical a-synucleinopathymodels. To this end, we posit that a
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win, fast fail paradigm [4] exploiting MSA-P phase II proof of
concept trials as a template disease for medications targeting aSYN
could accelerate drug development in a-synucleinopathies.
Employing such a MSA ﬁlter barrier could allow an earlier decision
whether a candidate compound effectively mediates neuro-
protection and, therefore, warrant further clinical validation (phase
III trials). Consequently, the number of phase III trials prone to
failure would decrease which, in turn, would increase the resources
that could be allocated to earlier drug development stages. Overall,
we suggest that an early MSA proof of concept trial has two major
implications for accelerating development of neuroprotective
strategies in PDwith aSYN inclusion pathology: (1) due to the time-
and cost-savings generated by reducing the number of negative
phase III trials, more resources would be available to earlier drug
development phases which consequently would increase the
number of candidate compounds being validated. (2) Rapidly pro-
gressive surrogate measures and the lack of effective symptomatic
treatment would enable relatively short-term, parallel group
design MSA trials to prove neuroprotective efﬁcacy. In this context,
it is crucial to reliably identify MSA-P patients early in the disease
course at the level of independent ambulation. This can be achieved
with current consensus criteria for possible MSA [54] which show
an excellent positive predictive value of 95% at ﬁrst clinic visit for aFig. 2. Modiﬁed quick win, fast fail drug development approach The ﬁgure illustrates pos
approach (B) in comparison to the current drug development and validation strategy (A). W
useful to pre-select the most promising candidate compounds and thereby substantially repost-mortem MSA diagnosis [80]. Nevertheless, due to the subop-
timal sensitivity of these criteria [80] the development and vali-
dation of highly sensitive and speciﬁc imaging and cerebrospinal
ﬂuid or plasma biomarker is a high priority objective in MSA
research.
However, it has to be acknowledged that the described para-
digm has certain shortcomings including the risk of false negative
MSA trials. If any doubt on the face validity of such a proof of
concept trial remains and a strong preclinical rational for a disease-
modifying efﬁcacy exists, a repetition of the trial in a PD setting
would be required to exclude a PD-speciﬁc mechanism of neuro-
protection. Vice versa, a positive MSA study does not necessarily
predict that the same interventionwill work in PD and in every case
a phase III study in PD will be required to conﬁrm efﬁcacy specif-
ically in PD. Difﬁculties in patient recruitment is another major
factor in slowing drug development. This is even more problematic
in rare disease, however, recruiting sufﬁcient patient numbers for
MSA is still possible as proven by the rifampicin and rasagiline MSA
trials [77,81]. Finally, the typical patient diagnosed with MSA is
likely to be considerably more disabled than the patient initially
diagnosed with PD and it is in newly diagnosed PD patients that
disease modifying therapies would be most useful. This dissimi-
larity in patient severity may limit the generalizability of ﬁndings in
trials between MSA and PD. However, if disease-modifying efﬁcacysible time- and cost-savings of a modiﬁed quick-win, fast fail proof of concept (PoC)
e posit that introduction of a MSA interventional trial as PoC ﬁlter barrier would be
duce the number of negative phase III trials being carried out.
F. Krismer et al. / Parkinsonism and Related Disorders 20 (2014) 793e799798of interventions targeting the effects of a-synucleinopathy lesions
can be shown in MSA subjects, this ﬁnding would strengthen
further therapeutic developments for PD. However, such MSA
ﬁndings can only be extrapolated to those PD patients who suffer
from an aSYN inclusion pathology.
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